2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Omics Technologies, Treatment Considerations, Biological Therapies, Infusion, Non-Biological Therapies, Anticoagulant Drugs, Women’s Health, Adverse Events, Biological Processes, Pathogenesis, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality of Care, Diseases, Bleeding and Clotting, Platelet Disorders, Thromboembolism, Thrombocytopenias, Thrombotic Disorders, Genetic Disorders, Lymphoid Malignancies, Lymphomas, Research, Clinical Research, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

3099 Anticoagulation outcomes in patients with active cancer and severe thrombocytopenia: A real-world comparative analysis

Kok Hoe Chan, MD, Jennifer Elizabeth Collins, PhD2
1 Charleston Area Medical Center, Charleston, West Virginia, United States
2 Charleston Area Medical Center, Charleston, West Virginia, United States

Background: Severe thrombocytopenia (platelet count <50,000/μL) presents a significant therapeutic dilemma when anticoagulation is indicated, requiring clinicians to balance competing risks of bleeding and thrombosis. Current guidelines generally recommend a platelet threshold of ≥50,000/μL for full-dose anticoagulation, with dose reduction or withholding therapy below this level. However, this threshold is based on limited evidence and was largely derived from studies in patients with acute leukemia, limiting its applicability to other causes of thrombocytopenia. The etiology of thrombocytopenia may substantially influence both bleeding and thrombotic risks. Patients with cancer-associated thrombocytopenia, in particular, remain at elevated risk for recurrent venous thromboembolism (VTE) despite low platelet counts.

Objective: To evaluate the risks and benefits of anticoagulation in adults with active cancer and severe thrombocytopenia using real-world data from the TriNetX Research Network.

Methods: This retrospective cohort study utilized de-identified electronic health record data from the TriNetX Research Network from 2010-2025. Adults with at least two platelet counts of <50,000/μL and a documented indication for anticoagulation (VTE, atrial fibrillation, portal vein thrombosis, or mechanical heart valve) were included. Patients reconceiving anticoagulation were compared with non-anticoagulation patients following 1:1 propensity score matching for demographics, comorbidities, anticoagulation indicators, and baseline thrombotic risk factors. Risk ratios (RRs) were used for binary outcomes and Kaplan-Meier log rank tests were used to assess survival. The primary outcome was major bleeding. Secondary outcomes included survival, clinically relevant non-major bleeding (CRNMB), and comparisons by anticoagulant class.

Results: After propensity score matching, 6,122 patients were included in each cohort with well-balanced baseline characteristics. Anticoagulation was associated with significantly worse short- and long-term survival. Ninety-day survival was significantly lower in the anticoagulated cohort (52.0% vs 58.4%; HR = 1.24, 95% CI: 1.18–1.31; p<0.001), and 1-year survival was similarly inferior. Rates of major bleeding were comparable between groups (14.3% vs 13.7%; p=0.322), as were rates of CRNMB (7.5% vs 7.8%; p=0.611). Subgroup analysis by anticoagulant class demonstrated important differences. Heparin (4,662 matched pairs) was associated with significantly worse 90-day survival (51.9% vs 57.7%; p<0.001) and increased rates of major bleeding (15.8% vs 13.9%; p=0.012) compared with the non-anticoagulated cohort. Low-molecular-weight heparin-based anticoagulants (1,837 matched pairs) were associated with lower 90-day survival (46.6% vs 55.3%; p<0.001) but lower rates of major bleeding (9.9% vs 12.6%; p=0.008) and CRNMB (5.2% vs 6.9%; p=0.038). Direct oral anticoagulants (885 matched pairs) demonstrated no significant differences in major bleeding or CRNMB, although survival remained lower (40.8% vs 45.8%; p = 0.011). Warfarin (151 matched pairs) was associated with the poorest survival; however, the sample size was relatively small, limiting definitive conclusions.

Conclusions: This study addresses an important evidence gap regarding anticoagulation management in patients with active cancer and severe thrombocytopenia. In this large real-world cohort, anticoagulation was associated with worse survival but not higher overall rates of major bleeding or CRNMB. Although residual confounding by indication cannot be excluded, differences observed among anticoagulant classes suggest that the safety profile of anticoagulation may vary substantially in this population. These findings may help inform individualized treatment decisions and provide a foundation for prospective studies in a patient population historically underrepresented in clinical trials.

Kok Hoe Chan, MD: No relevant conflicts of interest to declare.